MedTrace Logo

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

NCT06422884 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2026-02-24

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Conditions

Interventions

DRUG

ENV-101

oral tablet, dosed once a day

DRUG

Placebo

oral tablet, dosed once a day

Sponsors & Collaborators

  • Endeavor Biomedicines, Inc.

    lead INDUSTRY

Principal Investigators

  • Lisa Lancaster, M.D. · Endeavor Biomedicines

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Canada
  • France
  • Germany
  • Ireland
  • Italy
  • Malaysia
  • Mexico
  • New Zealand
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06422884 on ClinicalTrials.gov